Oral Vaccines Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

1 RESEARCH SCOPE

1.1 Research Product Definition

1.2 Research Segmentation

1.2.1 Product Type

1.2.2 Main product Type of Major Players

1.3 Demand Overview

1.4 Research Methodology

2 GLOBAL ORAL VACCINES INDUSTRY

2.1 Summary about Oral Vaccines Industry

2.2 Oral Vaccines Market Trends

2.2.1 Oral Vaccines Production & Consumption Trends

2.2.2 Oral Vaccines Demand Structure Trends

2.3 Oral Vaccines Cost & Price

3 MARKET DYNAMICS

3.1 Manufacturing & Purchasing Behavior in 2020

3.2 Market Development under the Impact of COVID-19

3.2.1 Drivers

3.2.2 Restraints

3.2.3 Opportunity

3.2.4 Risk

4 GLOBAL MARKET SEGMENTATION

4.1 Region Segmentation (2017 to 2021f)

4.1.1 North America (U.S., Canada and Mexico)

4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)

4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)

4.1.4 South America (Brazil,, Argentina, Rest of Latin America)

4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and Africa)

4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Live Attenuated Vaccines

4.2.2 Killed/Inactivated Vaccines

4.2.3 Recombinant Vaccines

4.2.4 Others

4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Polio

4.3.2 Rabies

4.3.3 Rotavirus

4.3.4 Cholera

4.3.5 HIV

4.3.6 Respiratory Infections

4.3.7 Influenza

4.3.8 Tuberculosis

4.3.9 Others

5 NORTH AMERICA MARKET SEGMENT

5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Live Attenuated Vaccines

5.2.2 Killed/Inactivated Vaccines

5.2.3 Recombinant Vaccines

5.2.4 Others

5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Polio

5.3.2 Rabies

5.3.3 Rotavirus

5.3.4 Cholera

5.3.5 HIV

5.3.6 Respiratory Infections

5.3.7 Influenza

5.3.8 Tuberculosis

5.3.9 Others

5.4 Impact of COVID-19 in North America

6 EUROPE MARKET SEGMENTATION

6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

6.1.5 Rest of Europe

6.2 Product Type Segmentation (2017 to 2021f)

6.2.1 Live Attenuated Vaccines

6.2.2 Killed/Inactivated Vaccines

6.2.3 Recombinant Vaccines

6.2.4 Others

6.3 Consumption Segmentation (2017 to 2021f)

6.3.1 Polio

6.3.2 Rabies

6.3.3 Rotavirus

6.3.4 Cholera

6.3.5 HIV

6.3.6 Respiratory Infections

6.3.7 Influenza

6.3.8 Tuberculosis

6.3.9 Others

6.4 Impact of COVID-19 in Europe

7 ASIA-PACIFIC MARKET SEGMENTATION

7.1 Region Segmentation (2017 to 2021f)

7.1.1 China

7.1.2 India

7.1.3 Japan

7.1.4 South Korea

7.1.5 Southeast Asia

7.1.6 Australia

7.1.7 Rest of Asia Pacific

7.2 Product Type Segmentation (2017 to 2021f)

7.2.1 Live Attenuated Vaccines

7.2.2 Killed/Inactivated Vaccines

7.2.3 Recombinant Vaccines

7.2.4 Others

7.3 Consumption Segmentation (2017 to 2021f)

7.3.1 Polio

7.3.2 Rabies

7.3.3 Rotavirus

7.3.4 Cholera

7.3.5 HIV

7.3.6 Respiratory Infections

7.3.7 Influenza

7.3.8 Tuberculosis

7.3.9 Others

7.4 Impact of COVID-19 in Europe

8 SOUTH AMERICA MARKET SEGMENTATION

8.1 Region Segmentation (2017 to 2021f)

8.1.1 Brazil

8.1.2 Argentina

8.1.3 Rest of Latin America

8.2 Product Type Segmentation (2017 to 2021f)

8.2.1 Live Attenuated Vaccines

8.2.2 Killed/Inactivated Vaccines

8.2.3 Recombinant Vaccines

8.2.4 Others

8.3 Consumption Segmentation (2017 to 2021f)

8.3.1 Polio

8.3.2 Rabies

8.3.3 Rotavirus

8.3.4 Cholera

8.3.5 HIV

8.3.6 Respiratory Infections

8.3.7 Influenza

8.3.8 Tuberculosis

8.3.9 Others

8.4 Impact of COVID-19 in Europe

9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION

9.1 Region Segmentation (2017 to 2021f)

9.1.1 GCC

9.1.2 North Africa

9.1.3 South Africa

9.1.4 Rest of Middle East and Africa

9.2 Product Type Segmentation (2017 to 2021f)

9.2.1 Live Attenuated Vaccines

9.2.2 Killed/Inactivated Vaccines

9.2.3 Recombinant Vaccines

9.2.4 Others

9.3 Consumption Segmentation (2017 to 2021f)

9.3.1 Polio

9.3.2 Rabies

9.3.3 Rotavirus

9.3.4 Cholera

9.3.5 HIV

9.3.6 Respiratory Infections

9.3.7 Influenza

9.3.8 Tuberculosis

9.3.9 Others

9.4 Impact of COVID-19 in Europe

10 COMPETITION OF MAJOR PLAYERS

10.1 Brief Introduction of Major Players

10.1.1 GlaxoSmithKline Plc.

10.1.2 PaxVax Corporation

10.1.3 Pfizer Inc

10.1.4 Merial, Inc.

10.1.5 Merck Sharp & Dohme Corp

10.1.6 VALNEVA Canada Inc.

10.1.7 QUíMICA SUIZA S.A

10.1.8 Immunitor, Inc

10.1.9 Aventis (Sanofi S.A.)

10.1.10 Serum Institute of India Pvt. Ltd

10.1.11 Swiss Serum and Vaccine Institute Berne

10.1.12 Bull Bio - NCIPD Ltd.

10.1.13 Vaxart, Inc.

10.1.14 Shantha Biotechnics

10.1.15 Crucell (Janssen Global Services, LLC)

10.2 Oral Vaccines Sales Date of Major Players (2017-2020e)

10.2.1 GlaxoSmithKline Plc.

10.2.2 PaxVax Corporation

10.2.3 Pfizer Inc

10.2.4 Merial, Inc.

10.2.5 Merck Sharp & Dohme Corp

10.2.6 VALNEVA Canada Inc.

10.2.7 QUíMICA SUIZA S.A

10.2.8 Immunitor, Inc

10.2.9 Aventis (Sanofi S.A.)

10.2.10 Serum Institute of India Pvt. Ltd

10.2.11 Swiss Serum and Vaccine Institute Berne

10.2.12 Bull Bio - NCIPD Ltd.

10.2.13 Vaxart, Inc.

10.2.14 Shantha Biotechnics

10.2.15 Crucell (Janssen Global Services, LLC)

10.3 Market Distribution of Major Players

10.4 Global Competition Segmentation

11 MARKET FORECAST

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

12 REPORT SUMMARY STATEMENT

Table Oral Vaccines Product Type Overview

Table Oral Vaccines Product Type Market Share List

Table Oral Vaccines Product Type of Major Players

Table Brief Introduction of GlaxoSmithKline Plc.

Table Brief Introduction of PaxVax Corporation

Table Brief Introduction of Pfizer Inc

Table Brief Introduction of Merial, Inc.

Table Brief Introduction of Merck Sharp & Dohme Corp

Table Brief Introduction of VALNEVA Canada Inc.

Table Brief Introduction of QUíMICA SUIZA S.A

Table Brief Introduction of Immunitor, Inc

Table Brief Introduction of Aventis (Sanofi S.A.)

Table Brief Introduction of Serum Institute of India Pvt. Ltd

Table Brief Introduction of Swiss Serum and Vaccine Institute Berne

Table Brief Introduction of Bull Bio - NCIPD Ltd.

Table Brief Introduction of Vaxart, Inc.

Table Brief Introduction of Shantha Biotechnics

Table Brief Introduction of Crucell (Janssen Global Services, LLC)

Table Products & Services of GlaxoSmithKline Plc.

Table Products & Services of PaxVax Corporation

Table Products & Services of Pfizer Inc

Table Products & Services of Merial, Inc.

Table Products & Services of Merck Sharp & Dohme Corp

Table Products & Services of VALNEVA Canada Inc.

Table Products & Services of QUíMICA SUIZA S.A

Table Products & Services of Immunitor, Inc

Table Products & Services of Aventis (Sanofi S.A.)

Table Products & Services of Serum Institute of India Pvt. Ltd

Table Products & Services of Swiss Serum and Vaccine Institute Berne

Table Products & Services of Bull Bio - NCIPD Ltd.

Table Products & Services of Vaxart, Inc.

Table Products & Services of Shantha Biotechnics

Table Products & Services of Crucell (Janssen Global Services, LLC)

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Oral Vaccines Market Forecast (Million USD) by Region 2021f-2026f

Table Global Oral Vaccines Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Oral Vaccines Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Oral Vaccines Market Forecast (Million USD) Share by Demand 2021f-2026f